Antiviral potency of a siRNA targeting a conserved region of coxsackievirus A24

Biochemical and Biophysical Research Communications

Volumn 376, Issue 2, 2008, Pages 389-394

  Jun, Eun Jung ^a   Nam, Young Ran ^a   Ahn, Jeonghyun ^a   Tchah, Hungwon ^a   Joo, Chul Hyun ^a   Jee, Youngmee ^b   Kim, Yoo Kyum ^a   Lee, Heuiran ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea National Institute of Health   (South Korea)

Author keywords

Acute hemorrhagic conjunctivitis; Antiviral effect; cis Acting replication element; Coxsackievirus A24; Small interfering RNA

Indexed keywords

SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONJUNCTIVA; COXSACKIE VIRUS A; COXSACKIE VIRUS A24; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; VIRUS GENOME;

ANTIVIRAL AGENTS; BASE SEQUENCE; CONSERVED SEQUENCE; CYTOPATHOGENIC EFFECT, VIRAL; ENTEROVIRUS C, HUMAN; HELA CELLS; HUMANS; RNA, SMALL INTERFERING; VIRUS REPLICATION;

COXSACKIEVIRUS;

EID: 53149138899     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.08.169     Document Type: Article

References (42)

1. Yin-Murphy M. Acute hemorrhagic conjunctivitis. Prog. Med. Virol. 29 (1984) 23-44
2. Wright P.W., Strauss G.H., and Langford M.P. Acute hemorrhagic conjunctivitis. Am. Fam. Physician 45 (1992) 173-178
3. Palacios G., and Oberste M.S. Enteroviruses as agents of emerging infectious diseases. J. Neurovirol. 11 (2005) 424-433
4. Park K., Lee K., Lee J., et al. Acute hemorrhagic conjunctivitis epidemic caused by coxsackievirus A24 variants in Korea during 2002-2003. J. Med. Virol. 78 (2006) 91-97
5. Dykxhoorn D.M., Novina C.D., and Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. 4 (2003) 457-467
6. Elbashir S.M., Harborth J., Lendeckel W., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
7. Leonard J.N., and Schaffer D.V. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther. 13 (2006) 532-540
8. Dykxhoorn D.M., Palliser D., and Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 13 (2006) 541-552
9. Van Regenmortel M.H.V., Fauquet C.M., Bishop D.H.L., et al. Picornaviridae (2000), Academic Press
10. Rueckert R.R. Picornaviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology. third ed. (1996), Lippincott-Raven, Philadelphia, PA Wloters Kluwer, 2007
11. Schubert S., Grunert H.P., Zeichhardt H., et al. Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J. Mol. Biol. 346 (2005) 457-465
12. Gitlin L., Karelsky S., and Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418 (2002) 430-434
13. Ahn J., Jun E.S., Lee H.S., et al. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J. Virol. 79 (2005) 8620-8624
14. Merl S., Michaelis C., Jaschke B., et al. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation 111 (2005) 1583-1592
15. Kim Y.J., Ahn J., Jeung S.Y., et al. Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model. Virus Genes 36 (2008) 141-146
16. Chung S.H., Lee J.H., Yoon J.H., et al. Multi-layered culture of primary human conjunctival epithelial cells producing MUC5AC. Exp. Eye Res. 85 (2007) 226-233
17. Ahn J., Joo C.H., Seo I., et al. All CVB serotypes and clinical isolates induce irreversible cytopathic effects in primary cardiomyocytes. J. Med. Virol. 75 (2005) 290-294
18. Lee H.S., Ahn J., Jee Y., et al. Universal and mutation-resistant anti-enteroviral activity: potency of small interfering RNA complementary to the conserved cis-acting replication element within the enterovirus coding region. J. Gen. Virol. 88 (2007) 2003-2012
19. Nilsson E.C., Jamshidi F., Johansson S.M., et al. Sialic acid is a cellular receptor for coxsackievirus A24 variant, an emerging virus with pandemic potential. J. Virol. 82 (2008) 3061-3068
20. Melnick J.L. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology. third ed. (1996), Lippincott-Raven, Philadelphia, PA
21. Goodfellow I., Chaudhry Y., Richardson A., et al. Identification of a cis-acting replication element within the poliovirus coding region. J. Virol. 74 (2000) 4590-4600
22. Brown K.M., Chu C.Y., and Rana T.M. Target accessibility dictates the potency of human RISC. Nat. Struct. Mol. Biol. 12 (2005) 469-470
23. Du Q., Thonberg H., Wang J., et al. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33 (2005) 1671-1677
24. Schubert S., Grunweller A., Erdmann V.A., et al. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J. Mol. Biol. 348 (2005) 883-893
25. Yoshinari K., Miyagishi M., and Taira K. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res. 32 (2004) 691-699
26. Judge A.D., Sood V., Shaw J.R., et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23 (2005) 457-462
27. van Ooij M.J., Vogt D.A., Paul A., et al. Structural and functional characterization of the coxsackievirus B3 CRE(2C): role of CRE(2C) in negative- and positive-strand RNA synthesis. J. Gen. Virol. 87 (2006) 103-113
28. Banerjee R., Echeverri A., and Dasgupta A. Poliovirus-encoded 2C polypeptide specifically binds to the 3′-terminal sequences of viral negative-strand RNA. J. Virol. 71 (1997) 9570-9578
29. Banerjee R., Weidman M.K., Echeverri A., et al. Regulation of poliovirus 3C protease by the 2C polypeptide. J. Virol. 78 (2004) 9243-9256
30. Gitlin L., Stone J.K., and Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J. Virol. 79 (2005) 1027-1035
31. Ameres S.L., Martinez J., and Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130 (2007) 101-112
32. Haley B., and Zamore P.D. Kinetic analysis of the RNAi enzyme complex. Nat. Struct. Mol. Biol. 11 (2004) 599-606
33. Rose S.D., Kim D.H., Amarzguioui M., et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res. 33 (2005) 4140-4156
34. Uematsu K., Seki N., Seto T., et al. Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. Anticancer Res. 27 (2007) 4239-4242
35. Lee N.S., Dohjima T., Bauer G., et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20 (2002) 500-505
36. Novina C.D., Murray M.F., Dykxhoorn D.M., et al. SiRNA-directed inhibition of HIV-1 infection. Nat. Med. 8 (2002) 681-686
37. Jacque J.M., Triques K., and Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 418 (2002) 435-438
38. Kim D.H., and Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8 (2007) 173-184
39. Hannon G.J., and Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 431 (2004) 371-378
40. Bitko V., Musiyenko A., Shulyayeva O., et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11 (2005) 50-55
41. Palliser D., Chowdhury D., Wang Q.Y., et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439 (2006) 89-94
42. Chappelow A.V., and Kaiser P.K. Neovascular age-related macular degeneration: potential therapies. Drugs 68 (2008) 1029-1036